Press release
Pipeline Assessment on Somatostatin Receptor Type 4 (SSTR4) with Analysis of Ongoing Trails Review in 2017
Pharmaceutical Industry Research Reports - MRH
Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1196637
According to the recently published report 'Somatostatin Receptor Type 4 (SSTR4) - Pipeline Review, H1 2017'; Somatostatin Receptor Type 4 (SSTR4) pipeline Target constitutes close to 6 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes.
Somatostatin Receptor Type 4 (SSTR4) - Somatostatin receptor type 4 is a protein encoded by the SSTR4 gene. The activity of receptor is mediated by G proteins which inhibits adenylyl cyclase. It mediates antiproliferative action of somatostatin in tumor cells. It is functionally coupled to inhibition of adenylate cyclase and activation of both arachidonate release and mitogen-activated protein (MAP) kinase cascade.
It also reviews key players involved in Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 1 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Hormonal Disorders, Metabolic Disorders and Oncology which include indications Chronic Pain, Acromegaly, Neuropathic Pain, Alzheimer's Disease, Cognitive Disorders, Dementia, Diabetic Retinopathy, Gastrointestinal Tumor, Neuroendocrine Tumors, Pancreatic Tumor and Pituitary ACTH Hypersecretion (Cushing Disease).
Make An Enquiry: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1196637
Scope
- The report provides a snapshot of the global therapeutic landscape for Somatostatin Receptor Type 4 (SSTR4)
- The report reviews Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Somatostatin Receptor Type 4 (SSTR4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Somatostatin Receptor Type 4 (SSTR4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Browse Full Report With TOC: http://www.marketresearchhub.com/report/somatostatin-receptor-type-4-sstr4-pipeline-review-h1-2017-report.html
About Market Research Hub:
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
Contact Us
90 State Street,
Albany, NY 12207,
United States
Toll Free: 866-997-4948 (US-Canada)
Tel: +1-518-621-2074
Email: press@marketresearchhub.com
Website: http://www.marketresearchhub.com/
Read Industry News At: https://www.industrynewsanalysis.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pipeline Assessment on Somatostatin Receptor Type 4 (SSTR4) with Analysis of Ongoing Trails Review in 2017 here
News-ID: 601516 • Views: …
More Releases from Pharmaceutical Research Reports [MRH]
Pipeline Analysis on Phenylalanine 4 Hydroxylase Reviewed by Company, Profiled D …
Market Research Hub (MRH) has recently publicized a new study to its vast repository, which is titled as “Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) - Pipeline Review, H1 2017”. This research study outlays comprehensive information on the Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration…
Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopepti …
According to the latest pipeline analysis, Aminopeptidase N (APN/CD13) acts as an exopeptidase and has been studied for decades. In recent years, it has been seen not only as a tumor-related target but also as a potential functional protein in various other physiological or pathological processes, such as analgesia, virus infection and inflammation. To elaborate further details on its global demand, a study titled “Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein…
Global Indoleamine 2, 3 Dioxygenase 1 Industry Vital Pipeline Review for the Fir …
The indoleamine 2, 3 Dioxygenase 1 or IDO1 market is developing since the cancer treatment sector relies heavily on its’ in-depth research and high-quality treatments. Looking into this huge potential, a new study has been added to the vast online repository of Market Research Hub (MRH), with the title ‘’Indoleamine 2, 3 Dioxygenase 1 (Indoleamine Pyrrole 2, 3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Pipeline Review, H1 2017‘’.…
More Releases for Somatostatin
Somatostatin Market: Driving Revolutionary Growth in Hormone Therapy Solutions
Market Overview and Strategic Significance
The global somatostatin market represents one of the most dynamic segments within the specialty pharmaceuticals industry, demonstrating exceptional growth potential as healthcare systems worldwide prioritize advanced endocrine disorder treatments. The global somatostatin market was valued at approximately USD 280 million in 2023 and is anticipated to reach USD 450 million by 2033, growing at a CAGR of 4.8% from 2024 to 2033. This substantial market expansion…
Somatostatin Market Qualitative and Quantitative Analysis By 2028
Somatostatin Market report provides key statistics on the state of the Market and is a valuable source of guidance and direction for companies and individuals interested in the market. The report focuses on global major leading companies providing information such as company profiles, sales, sales revenue, market share and contact information. Finally, the marketing, feasibility of new investment projects is assessed and overall research conclusions offered
An exclusive Somatostatin Market research…
Somatostatin Analogue Drug Market Trends, Growth, Analysis and Forecast - 2025
The global somatostatin analogue drug market is anticipated to showcase considerable growth during the forecast period (2020-2026). The rising FDA approvals, advancement in new treatment therapies, and new product launches are some of the key factors contributing to the growth of the hormone therapy replacement therapy market across the globe. According to the American Cancer Society, there are around 5,000 new carcinoid tumors diagnosed in the US each year. According…
Somatostatin Analogs Market : 2020 the Year on a Positive Note
Zion Market Research analysts forecast the latest report on "Global Somatostatin Analogs Market Set for Rapid Growth, to reach Value around USD 8.38 Billion by 2025", according to their latest report the Somatostatin Analogs Market report covers the overall and all-inclusive analysis of the Somatostatin Analogs Market with all its factors that have an impact on market growth. The Somatostatin Analogs Market's complete outline is crystal clear penned down in…
Newly Published Visiongain Report: Somatostatin Analogs Market Report 2019-2029
Somatostatin Analogs Market Report 2019-2029: By Type (Octreotide, Lanreotide, Pasireotide), Indication (Neuroendocrine Tumor (NET), Acromegaly), and Geography
Purchase full report or download free sample pages: https://www.visiongain.com/report/somatostatin-analogs-market-report-2019-2029/
Somatostatin Analogs – our new study reveals trends, R&D progress, and predicted revenues
Where is the Somatostatin Analogs market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2029, assessing data, trends,…
Explore the Global Somatostatin Market Opportunity Segmented by Region till 2023
Summary:
The Somatostatin Market Report elaborates market outlook including present scenario, competitive behavior and future growth prospects also sheds light on the various elements like type, application, SWOT analysis, business environment, Development Strategies, trends in upcoming years and key aspects behind the growth and demand of Somatostatin market is analyzed detailed in this report.
Somatostatin otherwise known as growth hormone-inhibiting hormone (GHIH), is a peptide hormone that regulates the endocrine system and…
